Skip to main content

Table 1 Baseline characteristics, by treatment group (N = 216)

From: Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border

Variables

DOT

SAT

Number of patients

n = 109

n = 107

Female; N (%)

45 (41)

41 (38)

Age group; N (%)

  

   3-7 years

34 (31)

20 (19)

   8-13 years

26 (24)

13 (12)

   ≥ 14 years

49 (45)

74 (69)

G6PD mutation status; N (%)

  

   Wild-type

81 (75)

84 (81)

   G6PD Mahidol: Homozygous

2 (2)

2 (2)

   G6PD Mahidol: Hemizygous

9 (8)

11 (10)

   G6PD Mahidol: Heterozygous

16 (15)

7 (7)

Body temperature at Day 0 (°C); Mean ± SD

37.8 ± 1.2

37.8 ± 1.2

Duration of fever pre-treatment; N (%)

  

   0-2 days

62 (57)

50 (47)

   3+ days

46 (43)

57 (53)

Parasite count at Day 0 (/µl); Geometric mean (range)

1,890 (32-75600)

2,533 (32-400000)

Gametocyte presence at Day 0; N (%)

45 (41)

37 (35)

Gametocyte count at Day 0 (/µl); Geometric mean (range)

141 (16-1600)

141 (16-8160)

P. vivax genotype (pvcs gene) infected at Day 0; N (%)

  

   VK210

95 (91)

84 (80)

   VK247

4 (4)

12 (11)

   VK210&VK247

5 (5)

9 (9)

Number of P. vivax genotype infections; N (%)

  

   Single

85 (82)

84 (80)

   Multiple infection

19 (18)

21 (20)